Pharma BD Deal Intelligence
GSK entered an exclusive strategic collaboration on May 11, 2026 with Sino Biopharmaceutical (SBP Group) via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) to accelerate the launch of bepirovirsen, a potential first-in-class antisense oligonucleotide for chronic hepatitis B (CHB), in mainland China. Under a supply-and-distribute structure, CTTQ purchases bepirovirsen from GSK under agreed supply terms and handles importation, distribution, hospital access (>5,000 medical centres) and promotional/non-promotional activities, while GSK remains the marketing authorisation holder and retains regulatory, quality, pharmacovigilance and global medical strategy responsibility; GSK is expected to book the sales of bepirovirsen supplied to CTTQ. The initial term is 5.5 years with mutual extension options. The agreement also grants GSK the right to review certain early-stage SBP Group pipeline assets to evaluate collaboration opportunities outside China. Financial terms were not disclosed. Bepirovirsen is under NMPA Priority Review in China and FDA Priority Review (Breakthrough Therapy Designation) in the US with an October 26, 2026 PDUFA target, supported by the Phase 3 B-Well 1/2 functional-cure readouts.